The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2011;(1): 34‑38

Read: 4003 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2011;(1):34‑38. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics — 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21—e181.
  2. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1—e90.
  3. Najafi F., Jamrozik K., Dobson A.J. Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure. Eur J Heart Fail 2009;11:472—479.
  4. Palaniswamy C., Mellana W.M., Selvaraj D.R., et al. Metabolic modulation: a new therapeutic target in treatment of heart failure. Am J Ther. Published Online First: 10 April 2010.
  5. Di Napoli P., Barsotti A. Prognostic relevance of metabolic approach in patients with heart failure. Curr Pharm Des 2009;15:883—892.
  6. Fragasso G., Spoladore R., Cuko A., et al. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase. Curr Clin Pharmacol 2007;2:190—196.
  7. Fantini E., Demaison L., Sentex E., et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994;26:949—958.
  8. Bertomeu-Gonzalez V., Bouzas-Mosquera A., Kaski J.C. Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol 2006;98:19J—24J.
  9. Onay-Besikci A., Ozkan S.A. Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovasc Ther 2008;26:147—165.
  10. Khan M., Meduru S., Mostafa M., et al. Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling. J Pharmacol Exp Ther 2010;333:421—429.
  11. Yin R.X., Liang W.W., Liu T.W., et al. Inhibitory effect of trimetazidine on cardiac myocyte apoptosis in rabbit model of ischemiae-reperfusion. Chin Med Sci J 2004;19:242.
  12. Wisel S., Khan M., Kuppusamy M.L., et al. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 2009;329:543—550.
  13. Park K.H., Park W.J., Kim M.K., et al. Effects of trimetazidine on endothelial dysfunction after sheath injury of radial artery. Am J Cardiol 2010;105:1723—1727.
  14. Liu X., Gai Y., Liu F., et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidaseeROSeCTGF pathway. Cardiovasc Res 2010;88:150—158.
  15. Gunes Y., Guntekin U., Tuncer M., et al. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009;24:277—282.
  16. Marazzi G., Gebara O., Vitale C., et al. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Adv Ther 2009;26:455—461.
  17. Belardinelli R., Lacalaprice F., Faccenda E., et al. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil 2008;15:533—540.
  18. Tuunanen H., Engblom E., Naum A., et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008;118:1250—1258.
  19. Belardinelli R., Cianci G., Gigli M., et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol 2008;51:611—615.
  20. Di Napoli P., Di Giovanni P., Gaeta M.A., et al. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 2007;154:602.e1—e5.
  21. Fragasso G., Palloshi A., Puccetti P., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992—998.
  22. Fragasso G., Perseghin G., De Cobelli F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006;27:942—948.
  23. Di Napoli P., Taccardi A.A., Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161—165.
  24. Vitale C., Wajngaten M., Sposato B., et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814—1821.
  25. Thrainsdottir I.S., von Bibra H., Malmberg K., et al. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 2004;44:101—108.
  26. Rosano G.M., Vitale C., Sposato B., et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.
  27. Fragasso G., Piatti P.M., Monti L., et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003;146:854.
  28. Belardinelli R., Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001;22:2164—2170.
  29. El-Kady T., El-Sabban K., Gabaly M., et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005;5:271—278.
  30. Brottier L., Barat J.L., Combe C., et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990;11:207—212.
  31. Sisakian H., Torgomyan A., Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy. Acta Cardiol 2007;62:493—499.
  32. Lopaschuk G.D. Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/lipid metabolism. Coron Artery Dis 1996;7:116—123.
  33. Di Napoli P., Taccardi A.A. Trimetazidine: the future of cardiac function? Future Cardiol 2009;5:421—424.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.